azd4604
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 20, 2021 (NCT04769869)
Timeline
Indications
Studied for
Mechanism of action
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06732882 | Phase 1 | Jan 13, 2025 | AstraZeneca |
| NCT06435273 | Phase 2 | Aug 5, 2024 | AstraZeneca |
| NCT06519968 | Phase 1 | Jul 15, 2024 | AstraZeneca, Parexel |
| NCT06157255 | Phase 1 | Feb 6, 2024 | AstraZeneca, Quotient |
| NCT06020014 | Phase 2 | Nov 6, 2023 | AstraZeneca |
| NCT04769869 | Phase 1 | Sep 20, 2021 | AstraZeneca, Parexel |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2021 |
| Parexel | For profit | 2 | 0 | 1 | 2021 |
| Quotient | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1